NYKODE THERAPEUTICS

Insiders Nykode Therapeutics

Equities

VACC

NO0010714785

Real-time Oslo Bors Other stock markets 05:25:07 2024-05-14 EDT			5-day change	1st Jan Change
13.67 ^NOK	-2.70%		-2.77%	-36.12%

04-19	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
04-19	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics AS Announces Management Changes	23-05-10	CI
Nykode Therapeutics : Nomination Committee Proposal	23-04-20	PU
Nykode Therapeutics Names CureVac Exec As New Chief Development Officer	22-06-13	MT
Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022	22-06-13	CI
Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors	22-05-11	CI
Nykode Therapeutics Names New Chair	21-12-15	MT
Vaccibody to Change Name to Nykode Therapeutics	21-11-23	MT
Vaccibody AS has Changed its Name to Nykode Therapeutics	21-11-23	CI
Vaccibody AS Announces Management Appointments, Effective June 1, 2021	21-05-11	CI
Vaccibody AS Appoints Dr. Volck as New Member of the Board	21-05-05	CI
Vaccibody AS Appoints Harald Gurvin as New Chief Financial Officer, Effective May 3, 2021	21-04-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW